SEC Comment Letter 0000000000-24-008591 to Cidara Therapeutics, Inc. (CDTX) (CIK 0001610618)
Cidara Therapeutics, Inc. (CDTX) (CIK 0001610618)
Date: July 29, 2024 · CIK: 0001610618 · Accession: 0000000000-24-008591
AI Filing Summary & Sentiment
File numbers found in text: 333-280919
Letter
July 29, 2024 Jeffrey Stein President and Chief Executive Officer Cidara Therapeutics, Inc. 6310 Nancy Ridge Drive, Suite 101 San Diego, California 92121 Re:Cidara Therapeutics, Inc. Registration Statement on Form S-1 Filed July 19, 2024 File No. 333-280919 Dear Jeffrey Stein: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Joshua Gorsky at 202-551-7836 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Charles J. Bair, Esq.
Show Raw Text
July 29, 2024
Jeffrey Stein
President and Chief Executive Officer
Cidara Therapeutics, Inc.
6310 Nancy Ridge Drive, Suite 101
San Diego, California 92121
Re:Cidara Therapeutics, Inc.
Registration Statement on Form S-1
Filed July 19, 2024
File No. 333-280919
Dear Jeffrey Stein:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Joshua Gorsky at 202-551-7836 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Charles J. Bair, Esq.